Evidence map›Paper›PMID 41224271›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Postpartum Hepatitis B Exacerbation Following Discontinuation of Nucleotide Analogue Therapy.

Ryo Takada, Soichiro Shimizu, Yuichi Yamazaki, Yumeo Tateyama, Toru Fukuchi, Tatsuma Murakami, Hiroki Tojima, Hiroaki Okamoto, Toshio Uraoka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryo TakadaDepartment of Hepatology, Kiryu Kosei General Hospital, Japan.
Soichiro ShimizuDepartment of Hepatology, Kiryu Kosei General Hospital, Japan.
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Yumeo TateyamaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Toru FukuchiDepartment of Hepatology, Kiryu Kosei General Hospital, Japan.
Tatsuma MurakamiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Hiroki TojimaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Hiroaki OkamotoDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan.
Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A woman in her 20s from Vietnam, an asymptomatic hepatitis B virus (HBV) carrier with a high viral load, was initiated on tenofovir disoproxil fumarate (TDF) at 31 weeks of gestation. TDF was discontinued after delivery; however, at eight weeks postpartum, she developed an acute exacerbation of hepatitis, characterized by elevated ALT levels and HBV DNA rebound. Although the risk of hepatitis flares following TDF discontinuation is generally considered low, this case highlights the potential for severe postpartum exacerbation and underscores the importance of considering continued antiviral therapy in the postpartum period.

Indexed as

Antiviral AgentsHepatitis BPregnancy Complications, InfectiousTenofovirDNA, ViralFemaleHepatitis B virusHumansPostpartum PeriodPregnancyAntiviral AgentsDNA, ViralTenofovirhepatitis B virus (HBV) carriernucleotide analogpostpartum acute exacerbationpregnant woman

Identifiers

PMID41224271
PMCPMC13423773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.